West Nile Virus Study (WNV)
Note that you will be prompted to log in or register an account
Accession Number
HLB01941414a
Study Type
Epidemiology Study
Collection Type
Open BioLINCC Study
See bottom of this webpage for request information
Study Period
09/2009 – 08/2011
NHLBI Division
DBDR
Clinical Trial URLs
N/A
Primary Publication URLs
https://www.ncbi.nlm.nih.gov/pubmed/23209411
Consent
Commercial Use Specimen Restrictions No
Non-Genetic Use Specimen Restrictions Based On Area Of Use No
Genetic Use Of Specimens Allowed? Yes
Genetic Use Area Of Research Restrictions No
Specific Consent Restrictions
None.
Objectives
The goal of the study was to enroll West Nile Virus (WNV) viremic donors into longitudinal natural history study, and characterize viral and immunological parameters.
Background
WNV is the third most important mosquito-borne virus after malaria and dengue virus. Humans are infected by mosquito bites, blood transfusion and organ transplantation. While most infections are asymptomatic or mild, causing a self-limiting febrile illness, the young, old and immunocompromised individuals are at greater risk for severe, sometimes fatal disease. WNV first appeared in the US in 1999 raising concerns for blood supply safety. In the US epidemic of 2002 there were 23 cases of transfusion-transmitted infections (Pealer et al., NEJM 2003). The virus has spread rapidly across the US such that by the end of 2003 there were 19,000 documented cases of WNV infections in the US with 750 fatalities. Testing the blood supply was implemented in 2003. By 2013, 12 transfusion-associated WNV transmissions have been documented in the US.
Participants
A total of 63 WNV+ subjects, of which 54 WNV+ had symptom questionnaires and longitudinal samples collected for characterization and inclusion in the database and repository. Approximately half the subjects developed symptomatic disease based on the study criteria.
Design
The subjects were identified when they presented themselves for blood donation and tested positive for WNV by nucleic acid testing (NAT). They were then contacted and enrolled in the study. On or around week 2 post blood donation, the subjects completed symptom questionnaires and provided a blood sample. Blood samples were also collected on weeks 3, 4, 6, 8, 12, and at 6, 9 and 12 months following the donation of the initial WNV+ blood donation that tested. Immunologic and viral studies were performed on the blood samples and aliquots were stored in the sample repository.
Additional Details
Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3 of the BioLINCC handbook describes the components of the review process
10/19/2017
Plasma | Packed Cells | Whole Blood | PBMC | Total | |
---|---|---|---|---|---|
Index | 531 | 98 | 0 | 0 | 629 |
Week 1 | 518 | 42 | 36 | 518 | 1114 |
Week 2 | 613 | 52 | 36 | 523 | 1224 |
Week 3 | 559 | 52 | 36 | 559 | 1206 |
Week 4 | 596 | 44 | 37 | 565 | 1242 |
Week 6 | 530 | 50 | 37 | 612 | 1229 |
Month 2 | 548 | 48 | 34 | 554 | 1184 |
Month 3 | 482 | 33 | 30 | 553 | 1098 |
Month 6 | 439 | 56 | 34 | 535 | 1064 |
Month 9 | 463 | 79 | 32 | 449 | 1023 |
Month 12 | 437 | 73 | 30 | 489 | 1029 |
10/19/2017
Plasma | ||
---|---|---|
Total number of subjects | Average volume (ml) per subject | |
Index | 38 | 27.87 |
Week 1 | 54 | 17.11 |
Week 2 | 54 | 20.20 |
Week 3 | 53 | 18.85 |
Week 4 | 53 | 20.06 |
Week 6 | 53 | 17.82 |
Month 2 | 49 | 19.06 |
Month 3 | 45 | 19.08 |
Month 6 | 47 | 16.64 |
Month 9 | 47 | 17.63 |
Month 12 | 46 | 16.89 |
Whole Blood | ||
---|---|---|
Total number of subjects | Average volume (ml) per subject | |
Week 1 | 36 | 7.83 |
Week 2 | 36 | 7.81 |
Week 3 | 36 | 7.78 |
Week 4 | 37 | 7.84 |
Week 6 | 37 | 7.81 |
Month 2 | 34 | 7.79 |
Month 3 | 30 | 7.87 |
Month 6 | 34 | 7.88 |
Month 9 | 32 | 7.63 |
Month 12 | 30 | 7.67 |
Packed Cells | ||
---|---|---|
Total number of subjects | Average vials per subject | |
Index | 37 | 2.65 |
Week 1 | 42 | 1.00 |
Week 2 | 52 | 1.00 |
Week 3 | 52 | 1.00 |
Week 4 | 44 | 1.00 |
Week 6 | 50 | 1.00 |
Month 2 | 48 | 1.00 |
Month 3 | 33 | 1.00 |
Month 6 | 41 | 1.37 |
Month 9 | 47 | 1.68 |
Month 12 | 43 | 1.70 |
PBMC | ||
---|---|---|
Total number of subjects | Average vials per subject | |
Week 1 | 54 | 9.59 |
Week 2 | 54 | 9.69 |
Week 3 | 53 | 10.55 |
Week 4 | 53 | 10.66 |
Week 6 | 53 | 11.55 |
Month 2 | 49 | 11.31 |
Month 3 | 45 | 12.29 |
Month 6 | 47 | 11.38 |
Month 9 | 47 | 9.55 |
Month 12 | 46 | 10.63 |
Please note that researchers must be registered on this site to submit a request, and you will be prompted to log in. If you are not registered on this site, you can do so via the Request button. Registration is quick, easy and free.
Resources Available
Specimens OnlyMaterials Available
- Packed Cells
- Peripheral Blood Mononuclear Cells
- Plasma
- Whole Blood
- More Details
Study Documents
Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message. If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.